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Abstract PHAS-I or the elF4E-binding protein 1 regulates the 
cap-binding activity of eIF4E by sequestering eIF4E. Binding of 
eIF4E to PHAS-I is regulated by phosphorylation of PHAS-I. 
PC12 cells were used to study the signal transduction pathway 
leading to phosphorylation of PHAS-I. Both EGF and NGF 
induced phosphorylation of PHAS-I. Wortmannin, a PI-3 kinase 
inhibitor, staurosporine, a PKC inhibitor, and rapamycin, a 
FRAP inhibitor all blocked the phosphorylation of PHAS-I. Of 
the three inhibitors, only wortmannin was able to inhibit MAPK 
phosphorylation. This excludes a role for MAPK in NGF- and 
EGF-induced PHAS-I phosphorylation in PC12 cells. Appar- 
ently, PHAS-I was phosphorylated in a PI-3 kinase-, PKC-, and 
FRAP-dependent manner after EGF or NGF stimulation. Only 
PI-3 kinase and FRAP are involved in the regulation of the basal 
level of PHAS-I phosphorylation. 
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1. Introduction 
Growth and differentiation of cells are accompanied by 
changes in protein synthesis. These changes are induced by 
phosphorylation of several proteins involved in translation 
initiation. The cap-binding eukaryotic initiation factor (eIF) 
4E is one of the proteins whose activity is regulated by 
changes in its phosphorylation state. Phosphorylation of 
eIF4E coincided with an increase in protein synthesis. 
Furthermore, phosphorylated eIF4E bound m7GTP, 
mTGpppG, and globin mRNA 34  times more efficiently 
than non-phosphorylated eIF4E [1]. Also, 80-85% of eIF4E 
present on the 48S initiation complex was phosphorylated; in 
contrast, only 50% of the free eIF4E was phosphorylated 
[2,3]. 
Recently, a different way to regulate eIF4E activity has 
been found. PHAS-I (or 4E-BP1), a heat- and acid-stable 
protein, is capable of binding eIF4E, and thereby is able to 
prevent he assembly of the eIF4F complex [4,5]. As PHAS-I 
and eIF4G bind to the same amino acid sequence in eIF4E 
[6,7], they are mutually exclusive in their binding to eIF4E [8]. 
PHAS-I is also regulated by phosphorylation. In vivo, 
PHAS-I is present in multiple forms, which are separated by 
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one-dimensional electrophoresis into three forms (c~, [3, and y), 
representing different forms of phosphorylation [9]. The ¢x and 
13 forms of PHAS-I are able to complex with eIF4E [4,5], 
thereby impairing the association of eIF4E with eIF4G, nec- 
essary for initiation. Phosphorylation f PHAS-I is increased 
after treatment of cells with insulin, epidermal growth factor 
(EGF), insulin-like growth factor I (IGF-I) or platelet-derived 
growth factor (PDGF) [10-12]. The signal transduction path- 
way leading to PHAS-I phosphorylation a d the in vivo ki- 
nase(s) of PHAS-I remain unclear. In vitro experiments 
showed that PHAS-I is a substrate of mitogen-activated pro- 
tein kinase (MAPK) [9,13], protein kinase C (PKC), and case- 
in kinase II [13]. However, MAPK was not able to phospho- 
rylate the histidine-tagged PHAS-I-eIF4E complex, and it was 
suggested that phosphorylation of PHAS-I by MAPK pre- 
vents reassociation with eIF4E [12]. Rapamycin, an immuno- 
suppressive agent that blocks activation of p70 s6K [14~16], 
abolished the insulin-induced phosphorylation f PHAS-I, in- 
dicating that PHAS-I was phosphorylated in a p70S6K-depen - 
dent manner. However, p70 s6K is not able to phosphorylate 
PHAS-I in vitro [9]. PD 098059, a MAP kinase kinase inhib- 
itor blocked MAPK activation, but did not affect PHAS-I 
phosphorylation [12]. Apparently, PHAS-I can be phospho- 
rylated in a MAPK- or p70S6K-dependent manner [11,13,17]. 
The increase in protein synthesis in PC12 cells after nerve 
growth factor (NGF) treatment is accompanied by eIF4E 
phosphorylation [18]. However, addition of epidermal growth 
factor (EGF) to PC12 cells did not lead to eIF4E phospho- 
rylation [19]. The role of PHAS-I phosphorylation i  PC12 
cells was studied after NGF and EGF treatment to determine 
whether PHAS-I phosphorylation is responsible for an in- 
crease in the availability of eIF4E for translation initiation. 
Furthermore, the signal transduction pathway involved in 
PHAS-I phosphorylation was investigated. Four important 
components of cellular signaling have been studied. MAPK 
activity was determined with a MAPK-shift assay, and the 
role of phosphatidylinositol-Y-OH kinase (PI-3 kinase), 
PKC, and FRAP were determined by using inhibitors of these 
kinases. 
2. Materials and methods 
2.1. Cell culture 
PCI2 cells were cultured in 1:1 DMEM and Ham's F12 (DF) con- 
taining 7.5% fetal calf serum. Cells were seeded in 60-mm diameter 
dishes and grown to a confluency of 60%. The cells were serum- 
starved for 2 h before the addition of EGF (50 ng/ml) or NGF (30 
ng/ml). The inhibitors wortmannin (100 nM), staurosporine (100 nM), 
and rapamycin (25 ng/ml) were added 10 min prior to the addition of 
growth factors. 
2.2. MAPK shift 
After treatment with growth factors, the cells were harvested in 100 
0014-5793196l$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
PH S00 1 4-5 793(96)0 1097-6 
166 
gl of Laemmli sample buffer [20]. Samples were heated for 10 min at 
95°C, sheared, and centrifuged for l0 min at 4°C. Supernatants were 
analyzed by SDS-PAGE (12.5% acrylamide, 0.075% bisacrylamide) 
[21]. The samples were run for 2 h at 200 V on a mini-gel system 
(LKB) to separate the non-phosphorylated and phosphorylated forms 
of MAPK. Proteins were blotted onto PVDF, the blot was incubated 
with polyclonal ERK2 antibody (a kind gift from J.L. Bos), and 
MAPK was detected using the alkaline phosphatase method. The 
amounts of non-phosphorylated and phosphorylated forms of 
MAPK were quantified with a densitometer (Molecular Dynamics). 
2.3. Phosphorylation of PHAS-I 
The samples used for the MAPK-shift assay were also analyzed by 
SDS-PAGE (13.5%) [20] to separate the c~-, ~-, and 7-forms of PHAS- 
I. Proteins were blotted onto PVDF, and PHAS-I was detected using 
a polyclonal rabbit antibody raised against bacterially expressed His- 
tagged PHAS-I [13]. The phosphorylation state of PHAS-! was quan- 
tified with a densitometer (Molecular Dynamics). 
2.4. Dephosphorylation f PHAS-I 
PCI2 cells were serum-starved for 2 h, and treated with NGF for 0 
or 60 min. The cells were harvested in PBS containing 10 mM EDTA, 
rinsed once with PBS, and once with CIP buffer (10 mM ZnCI,, 10 
mM MgCI2, 100 mM Tris-HCl pH 8.3). Cells were lysed in CIP buffer 
by freeze-thawing three times. About 50 l.tg of cell lysate was incu- 
bated for 16 h at 37°C with 2.5 units of calf intestine alkaline phos- 
phatase (CIP), and after addition of an extra 2.5 units for 4 h at 56°C. 
The samples were analyzed by SDS-PAGE (13.5%,) and immunoblot- 
ting as described above. 
2.5. Association of PHAS-I and elF4E 
Cells were serum-starved for 2 h and treated with NGF for 0 or 60 
min. After washing with PBS, the cells were lysed with 400 gl 10 mM 
HEPES, pH 7.4, adjusted with KOH, 50 mM [3-glycerophosphate, 0.2 
mM EDTA, 0.5'7. Nonidet-P40, 100 mM KC1, 7 mM 13-mercaptoetha- 
nol, 0.2 mM NaaVO4, 0.2 mM benzamidine, and 4 ~tg leupeptin per 
ml. The lysates were centrifuged at 10000×g to remove cell debris 
and the supernatant was used to purify eIF4E. The supernatant was 
incubated with 5 I.tl packed mYGTP Sepharose, supplemented with 15 
gl packed Sepharose 4B to increase the pellet volume. After 1 h the 
beads were washed 4 times with lysis buffer and eIF4E was eluted 
with Laemmli sample buffer. Eluted eIF4E and PHAS-I were ana- 
lyzed by SDS-PAGE and immunoblotting. 
2.6. $6 phosphorylation assay 
Cells were treated with EGF or NGF in the absence or presence of 
inhibitors for the times indicated in the figures. The cells were har- 
vested in a buffer containing 20 mM Tris-HCl pH 7.6, 1% Triton 
X-100, 50 mM 13-glycerophosphate, 0.2 mM EDTA, 0.2 mM 
EGTA, 1 mM sodium molybdate, 10% glycerol, 100 mM KC1, 4 ~tg 
leupeptin/ml, 0.2 mM benzamidine, 0.2 mM Na3VO~, and 7 mM 
[~-mercaptoethanol. Approx. 30 ng of cell extract was incubated at 
30°C for 15 min in the presence of 4 gg of 80S ribosomes derived 
from reticulocytes, 10 mM HEPES adjusted with KOH to pH 7.5, 100 
mM KAc, 0.2 mM EDTA, 100 gM [y-32p]ATP (spec. act. 2200 dpm/ 
pmol), 10 mM MgAc2, and 7 mM I~-mercaptoethanol i  a total vol- 
ume of 10 gl. The reaction was stopped by adding Laemmli sample 
buffer. The samples were heated for 5 min at 95°C, and analyzed by 
SDS-PAGE (12.5"/o) and autoradiography. $6 phosphorylation was 
quantified with a phospho-imager (Molecular Dynamics). This assay 
is specific for p70 s~;K activity [22]. 
3. Results 
3.1. PHAS- l  phosphorylation in PC12 cells" 
PC12 ceils were treated with NGF or EGF  for different 
time-periods (Fig. I A). Addit ion of NGF as well as EGF  
led to a mobil ity shift caused by phosphorylat ion of PHAS- 
I, as will be addressed in Fig. 2. The phosphorylated y-form 
changed from 15 to 44% for NGF,  and from 16 to 57"/,, for 
EGF.  The EGF response returned to basal level after 30 min, 
in contrast o the NGF response which lasted for 60 rain (Fig. 
1B). Treatment of the cells with either NGF or EGF  in the 
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presence of wortmannin,  a potent inhibitor of PI-3 kinase [23], 
did not induce PHAS-I  phosphorylat ion (Fig. 1A,B), suggest- 
ing phosphorylat ion of PHAS-I  via activation of PI-3 kinase. 
Activation of the MAPK signal transduction pathway by 
NGF and EGF was measured by the shift from unphospho- 
rylated to phosphorylated MAPK by SDS-PAGE [24]. Both 
growth factors induced a rapid phosphorylat ion of MAPK 
(Fig. I C) as described earlier for these cells [25]. After NGF 
addition the amount  of phosphorylated MAPK changed from 
15% to 51% at 15 min, and remained at 40'70 up to 60 min. 
EGF  addition led to an increase in phosphorylated MAPK 
from 10% to 47% at 5 rain, which declined to basal level at 60 
min. The amount  of phosphorylated MAPK only increased 
from 18% to a maximum of 30% at 15 min when cells were 
treated with NGF in the presence of wortmannin,  and from 
11% to 30% at 5 min after EGF  treatment in the presence of 
wortmannin  (Fig. 1C). MAPK phosphorylat ion (11%) was 
not detectably changed in the presence of wortmannin.  
3.2. Dephosphorylation of  PHAS- I  and association with elF4E 
Insulin-induced phosphorylat ion of PHAS- I  in rat adipo- 
cytes [12,13], and in rat adipose tissue [5] was accompanied 
by dissociation of PHAS- I  from eIF4E [5,13]. We wanted to 
know whether growth factors also regulated the association of 
PHAS-I  and eIF4E in PC12 cells, depending upon the phos- 
phorylat ion state of PHAS-I.  To this end, PC12 cells were 
treated for 0 or 60 rain with NGF.  NGF induced a shift in 
PHAS-I  to the slower migrating, phosphorylated forms (Fig. 
2A, upper panel). Even though NGF induced only a small 
increase in PHAS-I  phosphorylat ion in PC12 cells, this in- 
crease led to dissociation of PHAS-I  from eIF4E (Fig. 2A, 
lower panel). The amount  of e lF4E recovered was compar- 
able. Similar results were shown for insulin-stimulated skeletal 
muscle cells [26]. The results suggest hat eIF4E activity can 
be regulated by PHAS- I -e IF4E complex formation after NGF 
treatment in PCI2 cells. 
The 3 forms of PHAS-I ,  as revealed by one-dimensional 
electrophoresis, are generally assumed to arise from phos- 
phorylat ion of the s - fo rm to the 13- and y-forms. Studies 
with 32p labeling and two-dimensional separation resulted in 
identification of 2 labeled forms of PHAS-I,  in contrast o the 
14 spots identified by immunoblott ing [10,12]. To establish the 
relationship between the c~-, [3-, and y-forms, extracts of PC12 
cells were treated with alkaline phosphatase. Alkaline phos- 
phatase treatment led to conversion from y to ~ (Fig. 2B), but 
not from the ~- to wform,  showing that at least the y-form 
was a phosphorylated form of PHAS-I.  The lack of conver- 
sion to the c~-form will be discussed later. 
3.3. The role o[ PKC in PHAS- I  phosphorylation 
PKC is able to phosphorylate PHAS-I  in vitro [9]. The role 
of PKC in PHAS-I  phosphorylat ion i vivo was determined 
by treating PC12 cells with NGF or EGF  in the presence of 
staurosporine, a PKC inhibitor [27,28] (Fig. 3). Phosphoryla- 
tion of PHAS-I  was induced by NGF or EGF  addition, simi- 
lar to the results in Fig. 1. Treatment of cells in the presence 
of staurosporine blocked the effect of NGF and EGF on 
PHAS-I  phosphorylat ion completely (Fig. 3A,B), suggesting 
a major role for PKC in the phosphorylat ion of PHAS-I  in 
PC12 cells. 
MAPK phosphorylat ion i duced by EGF was not blocked 
by staurosporine as expected, because MAPK is activated by 
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Fig. I. Effect of wortmannin on NGF- and EGF-induced PHAS-I and MAPK phosphorylation. PCI2 cells were treated without ( - )  or with 
(+) NGF or EGF in the absence ( - )  or presence (+) of wortmannin for the times indicated. (A) Phosphorylation state of PHAS-I analyzed by 
SDS-PAGE and Western blotting. (B) Quantification of the phosphorylation state of PHAS-I. The different forms of PHAS-I are given as a 
percentage of the total amount of PHAS-I. The quantification of PHAS-I phosphorylation i  the absence of wortmannin is a mean from three 
independent experiments. (C) MAPK phosphorylation, shown as a shift from the unphosphorylated to the phosphorylated form of MAPK, 
was analyzed by SDS-PAGE, and Western blotting. 
EGF  in a PKC- independent way [25]. Also, staurosporine 
alone did not influence MAPK phosphorylat ion (Fig. 3C). 
3.4. PHAS- I  phosphorylation via FRAP 
PHAS-I  is phosphorylated after PDGF,  IGF- I ,  or insulin 
treatment in a rapamycin-sensitive way [11,12]. Furthermore,  
the experiments with wortmannin  (Fig. 1) and staurosporine 
(Fig. 3) showed no correlation between phosphorylat ion of 
PHAS-I  and MAPK activation after NGF or EGF  treatment. 
To assess the role of FRAP in PHAS-I  phosphorylat ion i  
PC12 cells after NGF and EGF addition, we used the inhibi- 
tor rapamycin (Fig. 4). NGF-  as well as EGF- induced PHAS- 
I phosphorylat ion was abolished by the addit ion of rapamycin 
(Fig. 4A,B). 
Rapamycin did not influence the MAPK-shi f t  induced by 
NGF (Fig. 4C). This is in agreement with data from the 
l iterature describing that rapamycin had no effect on 
MAPK activity in 3T3-L1 adipocytes as measured by 
MAPK-mediated phosphorylat ion of myelin basic protein 
[121. 
3.5. NGF- and EGF-induced activation o f  p70 s6K 
The role of FRAP in PHAS-I  phosphorylat ion prompted us 
to investigate the activation of p70 S6K, which is downstream 
of FRAP.  The activity of p70 s6K was measured by its ability 
to phosphorylate the r ibosomal $6 protein (Fig. 5). Addit ion 
of NGF led to a 350% increase in p70 s~K activity, which was 
prevented by staurosporine and rapamycin, and strongly di- 
minished by wortmannin (Fig. 5A). EGF  addit ion led to a 
50"/0 increase in p70 s~K activity with a maximum at 30 rain 
(Fig. 5B). The p70 sGK activation was completely blocked by 
wortmannin,  staurosporine, and rapamycin. The activation of 
A B 
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PHAS-I 
Fig. 2. Dephosphorylation of PHAS-I and its association with 
eIF4E. (A) PC12 cells were treated for 0 or 60 min with NGF, and 
eIF4E was purified to determine the association of PHAS-I with 
eIF4E. (Upper panel) Total cell extract. (Lower panel) m;GTP 
Sepharose purified. (B) Untreated cell extracts were incubated with 
alkaline phosphatase as described in Section 2. The resulting West- 
ern blot is shown. AP, alkaline phosphatase treated. 
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Fig. 3. Effect of staurosporine on NGF- and EGF-induced PHAS-I and MAPK phosphorylation. PC12 cells were treated without (-) or with 
(+) NGF or EGF in the absence (-) or presence (+) of staurosporine for the times indicated. (A) Analysis of the different forms of PHAS-I. 
(B) Quantification of panel A was performed as in Fig. 1. (C) Analysis of MAPK phosphorylation. 
p70 s6K by NGF treatment was more severe and prolonged 
than by EGF. 
3.6. Pathways leading to PHAS- I  phosphorylation 
Wortmannin, staurosporine, and rapamycin were also 
tested for their effect on PHAS-I phosphorylation when incu- 
bated in the absence of growth factors (Fig. 6). In control 
cells, 8% of PHAS-I was in the c(-form, 34% in the 13-form 
and 60% in the "/-form. After 1 h of incubation with wort- 
mannin, the c(-form increased to 20%, the J3-form to 78°/,,, and 
the 7-form declined to 2%. The effects were similar after 2 and 
3 h, but less apparent. Addition of staurosporine hardly in- 
fluenced the phosphorylation state of PHAS-I. Rapamycin on 
the other hand, had the strongest effect of the three inhibitors. 
After 3 h, 80% of PHAS-I was present in the c(-form, and only 
a small amount in the ~-form (14%), or ` /-form (6%). 
4. Discussion 
The activity of eIF4E can be regulated in at least two dif- 
ferent manners. First, association of eIF4E with PHAS-I, or 
the eIF4E-binding protein, prevents assembly of the eIF4F 
complex and thereby initiation of translation [6,8]. Second, 
the activity of eIF4E is positively correlated with its phos- 
phorylation state, as described in Section 1. NGF and EGF 
influence protein synthesis in different manners, as NGF is 
able to induce eIF4E phosphorylation in PC12 cells, whereas 
EGF is not [19]. Therefore, the role of PHAS-I phosphoryla- 
tion in the regulation of eIF4E activity in PCI2 cells was 
determined. 
Both EGF and NGF induced phosphorylation f PHAS-I 
(Fig. 1), which released eIF4E from PHAS-I (Fig. 2A), mak- 
ing eIF4E available for translation [5,13]. Regulation of 
eIF4E activity exclusively by PHAS-I phosphorylation and 
not by eIF4E phosphorylation, has been described for insulin 
treatment of diabetic rats [29], resembling our result with 
EGF and PC12 cells (Figs. 1, 3 and 4). 
The slower migrating forms of PHAS-I are known as the 
phosphorylated 13- and 7-forms [13]. That [3 and y are the 
phosphorylated forms is supported by several iterature data 
and results hown in this report. First, the 3,-form of PHAS-I 
can be converted to the 13-form by alkaline phosphatase treat- 
ment (Fig. 2B), showing that the 7-form is indeed a phos- 
phorylated form of PHAS-I. The inability of alkaline phos- 
phatase to convert he ~-form may be due to inaccessibility of
the phosphate residue or a difference in amino acid residues 
that are dephosphorylated. It has been shown that PHAS-I 
can be phosphorylated at serine as well as threonine residues 
[10]. Second, azp labeling of cells showed two phoshorylated 
PHAS-I forms [4,9,30], and their migration on SDS-PAGE 
indicates that these phosphorylated forms are the [3- and 
y-form. 
NGF- and EGF-induced PHAS-I phosphorylation was also 
studied in the presence of the PI-3 kinase inhibitor wortman- 
nin, the PKC inhibitor staurosporine, and the FRAP inhibitor 
rapamycin, to determine the involvement of these signal trans- 
duction components in the pathway leading to PHAS-I phos- 
phorylation (Figs. 1, 3 and 4). All three inhibitors abolished 
the effect of NGF and EGF on PHAS-I phosphorylation, 
showing that PI-3 kinase, PKC, and FRAP are components 
of the PHAS-I phosphorylation pathway(s). 
Inhibition of PI-3 kinase blocked NGF- and EGF-induced 
PHAS-I phosphorylation i  PC12 cells. The involvement of 
PI-3 kinase in PHAS-I phosphorylation has also been shown 
for insulin treatment of 32D cells overexpressing the insulin 
receptor [30], and for serum treatment of 293 cells [31]. 
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Fig. 4. Effect of rapamycin on NGF-  and EGF-induced PHAS-I and MAPK phosphorylation. PC12 cells were treated without ( - )  or with (+) 
NGF or EGF in the absence ( - )  or presence (+) of rapamycin for the times indicated. (A) Phosphorylation state of PHAS-I. (B) Quantifica- 
tion of the phosphorylation state of PHAS-I. The three forms of PHAS-I were analyzed as described in Fig. 1. (C) Analysis of MAPK phos- 
phorylation. 
Although wortmannin also inhibited MAPK phosphorylation 
partially, the results with staurosporine and rapamycin 
showed that MAPK activation is not involved in the NGF- 
and EGF-induced PHAS-I phosphorylation (as discussed be- 
low). 
Our results and literature data suggest hat PHAS-I phos- 
phorylation is most likely downstream of p70 s6K. This is 
strongly supported by the kinetics of p70 srK activation and 
PHAS-I phosphorylation after NGF or EGF treatment of 
PC12 cells, which were very similar (Figs. 1 and 5). Also, 
rapamycin, staurosporine, as well as wortmannin blocked 
PHAS-I phosphorylation a d p70 srK activation. Furthermore, 
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Fig. 5. Activation of p70 s6K by EGF and NGF.  PC12 cells were treated with EGF or NGF for the times indicated. Cell extracts were incu- 
bated in the presence of 80S ribosomes and [y-32P]ATP and analyzed by SDS-PAGE and autoradiography. Phosphorylation of the ribosomal 
$6 protein (as shown in the insets for the 30 min time point) was quantified with the phospho-imager (Molecular Dynamics). - ,  no addition; 
N, 30 min NGF;  NR, 30 min NGF + rapamycin; NS, 30 min NGF + staurosporine; NW, 30 min NGF + wortmannin. In the case of  EGF, N 
is replaced by an E. (A) NGF-induced p70 srK activity. (B) EGF-induced p70 srK activity. (e) NGF or EGF, (11) growth factor+rapamycin, 
( • ) growth factor + staurosporine, ( • ) growth factor + wortmannin. 
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Fig. 6. Effect of wortmannin, staurosporine, and rapamycin on PHAS-I phosphorylation. PCl2 cells grown in the presence of 7.5% serum were 
treated with wortmannin, staurosporine, or rapamycin for 1, 2, or 3 h. PHAS-I phosphorylation was analyzed and quantified. The c~-form (O), 
the [3-form (11), and the 7-form ( • ) are given as a percentage of the total amount of PHAS-I. 
similar results with rapamycin were obtained with insulin 
treatment of adipocytes, and PDGF and IGF- I  treatment of 
aortic smooth muscle cells [11,12], and concomitant activation 
of p70 s6t': and phosphorylation of PHAS-I was also reported 
for insulin and serum stimulation of 293 cells [31]. However, 
bifurcation of the signalling pathway downstream of FRAP 
and upstream of p70 s6K cannot be excluded; p70 s~K activa- 
tion and PHAS-I phosphorylation might occur in parallel. 
Treatment of cells with the inhibitors in the absence of 
growth factors gave us more insight into the regulation of 
PHAS-I  phosphorylation i normal growing cells. Wortman- 
nin and rapamycin induced PHAS-I  dephosphorylation (Fig. 
6), showing that PI-3 kinase and FRAP are components of 
the signalling pathway involved in the basal level of PHAS-I 
phosphorylation. On the other hand, phosphorylation of 
PHAS-I  by PKC, as found in vitro [9] and after NGF or 
EGF stimulation (Fig. 3), does not seem to be involved in 
the basal level of PHAS-I  phosphorylation, as staurosporine 
showed no effect on PHAS-I  phosphorylation (Fig. 6). 
A possible role of MAPK activation in PHAS-I phospho- 
rylation was also determined. MAPK was phosphorylated 
after NGF and EGF  addition, coinciding with PHAS-I phos- 
phorylation. However, only wortmannin was able to inhibit 
MAPK phosphorylation (Fig. 1C), whereas all three inhibi- 
tors abolished the effect of NGF and EGF on PHAS-I phos- 
phorylation. This clearly showed that the MAPK pathway is 
not involved in NGF-  and EGF-induced PHAS-I phosphoryl- 
ation in PC12 cells. This finding is not very surprising, be- 
cause MAPK only phosphorylated the co-form of PHAS-I 
[12], which is hardly changed after NGF and EGF addition 
to PC12 cells (Figs. 1, 3 and 4), and no involvement of 
MAPK in the 13-'/ conversion has been shown. So far, no 
involvement of MAPK in a growth factor-induced PHAS-I 
phosphorylation has been found [11,12,26,31], although 
MAPK very efficiently phosphorylates PHAS-I in vitro 
[9,12,13]. 
Regulation of PHAS-I phosphorylation by multiple path- 
ways is supported by several literature data. It has been 
shown that PHAS-I  is mostly phosphorylated at serine resi- 
dues in control cells, but at threonine residues in insulin-treat- 
ed cells [10]. This suggests that more than one kinase is in- 
volved in PHAS-I  phosphorylation. In vitro, three different 
kinases, MAPK,  PKC, and casein kinase II have been shown 
to phosphorylate PHAS-I  at distinct sites [9]. Furthermore, an 
increase in cAMP levels induced by forskolin was able to 
decrease activation of p70 s~K induced by PDGF and IGF-I,  
thereby decreasing PHAS-I phosphorylation [11]. This sug- 
gests an inhibitory role for cAMP-dependent protein kinase 
in the PHAS-I phosphorylation pathway. 
In summary, this paper provides evidence that PI-3 kinase, 
PKC, as well as FRAP are involved in the regulation of NGF-  
and EGF-induced PHAS-I  phosphorylation in PCI2 cells. 
Furthermore, PI-3 kinase, FRAP,  but not PKC are involved 
in the regulation of the basal level of PHAS-I phosphoryla- 
tion. 
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